Zobrazeno 1 - 10
of 1 652
pro vyhledávání: '"FLT3-ITD"'
Autor:
Brunno Gilberto Santos de Macedo, Manuela Albuquerque de Melo, Diego Antonio Pereira-Martins, João Agostinho Machado-Neto, Fabíola Traina
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Beyond its clinical diversity and severity, acute myeloid leukemia (AML) is known for its complex molecular background and for rewiring biological processes to aid disease onset and maintenance. FLT3 mutations are among the most recurring mo
Externí odkaz:
https://doaj.org/article/313905fa2cd14384a761f03fb64759d9
Autor:
Chuhong Hu, Yvyin Zhang, Jie Yang, Yanli Xu, Tingfen Deng, Yumiao Li, Shilin Xu, Shunqing Wang, Peihong Wang
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is a common mutation type in acute myeloid leukemia (AML) and is usually associated with poor patient prognosis. With advancements in molecular diagnostics and the
Externí odkaz:
https://doaj.org/article/8009670eecd249c4ad38edcc32956240
Autor:
Hongbo He, Jun Li, Weijing Li, Xiaoxi Zhao, Tianlin Xue, Shuguang Liu, Ruidong Zhang, Huyong Zheng, Chao Gao
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Acute myeloid leukemia (AML), which has distinct genetic abnormalities, has unique clinical and biological features. In this study, the incidence, clinical characteristics, induction treatment response, and outcomes of a large cohort of Chinese AML p
Externí odkaz:
https://doaj.org/article/715ad85e678145d39a1564a0dfb98e29
Autor:
Christoph Hieber, Al-Hassan M. Mustafa, Sarah Neuroth, Sven Henninger, Hans-Peter Wollscheid, Joanna Zabkiewicz, Michelle Lazenby, Caroline Alvares, Siavosh Mahboobi, Falk Butter, Walburgis Brenner, Matthias Bros, Oliver H. Krämer
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 177, Iss , Pp 117076- (2024)
Hyperactive FMS-like receptor tyrosine kinase-3 mutants with internal tandem duplications (FLT3-ITD) are frequent driver mutations of aggressive acute myeloid leukemia (AML). Inhibitors of FLT3 produce promising results in rationally designed cotreat
Externí odkaz:
https://doaj.org/article/92a388417b2242c48063d7ece8629a1e
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
FLT3-ITD is a type of poor prognostic factors in acute myeloid leukemia (AML) disease. Gilteritinib, the second-generation FLT3 tyrosine kinase inhibitor, improved the overall survival of patients with relapsed/refractory FLT3-mutated AML in the ADMI
Externí odkaz:
https://doaj.org/article/dc73fdbc10a1458bb84ffdebd0482c4b
Autor:
Julie Bergeron, Jose-Mario Capo-Chichi, Hubert Tsui, Etienne Mahe, Philip Berardi, Mark D. Minden, Joseph M. Brandwein, Andre C. Schuh
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10410-10436 (2023)
FMS-like tyrosine kinase 3 (FLT3) mutations are detected in approximately 20–30% of patients with acute myeloid leukemia (AML), with the presence of a FLT3 internal tandem duplication (FLT3-ITD) mutation being associated with an inferior outcome. A
Externí odkaz:
https://doaj.org/article/1416eca2cc7b4404a0ee2c558a41f7d4
Autor:
Enbo Chen, Changqing Jiao, Jian Yu, Yu Gong, Duo Jin, Xiaoyu Ma, Jianling Cui, Zhonghui Wu, Junjie Zhou, Haixia Wang, Bobing Su, Jian Ge
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21615-21626 (2023)
Abstract Background The European LeukemiaNet (ELN) risk classification system for acute myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk classification system modified risk genes including CEBPA mutation status, myelodys
Externí odkaz:
https://doaj.org/article/b81765de247d4da5bae2290b01aa10a5
Autor:
Xinhua Xiao, Peihong Wang, Weina Zhang, Jiayi Wang, Mansi Cai, Hua Jiang, Yingli Wu, Huizhuang Shan
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation accounts for a large proportion of AML patients and diagnosed with poor prognosis. Although the prognosis of FLT3-ITD AML
Externí odkaz:
https://doaj.org/article/90f6a4dd506143818d2808e14ba4d0ba
Autor:
D Sorcini, A Stella, A Scialdone, S Sartori, A Marra, R Rossi, F De Falco, FM Adamo, E Dorillo, C Geraci, R Arcaleni, C Rompietti, A Esposito, L Moretti, MG Mameli, MP Martelli, B Falini, P Sportoletti
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1100-1104 (2023)
Abstract One‐third of newly diagnosed adult acute myeloid leukaemia (AML) carry FLT3 mutations, which frequently occur together with nucleophosmin (NPM1) mutations and are associated with worse prognosis. FLT3 inhibitors are widely used in clinics
Externí odkaz:
https://doaj.org/article/4c38b29289274a7990c345b01979a9de
Autor:
Konstantin Bogdanov, Ekaterina Kudryavtseva, Yulia Fomicheva, Irina Churkina, Elza Lomaia, Larisa Girshova, Yuri Osipov, Andrey Zaritskey
Publikováno v:
Pathophysiology, Vol 30, Iss 3, Pp 296-313 (2023)
Mutations in the FLT3 gene not only lead to abnormalities in its structure and function, but also affect the expression of other genes involved in leukemogenesis. This study evaluated the expression of genes that are more characteristic of neuroblast
Externí odkaz:
https://doaj.org/article/4bf311b86da94bdd97db5ba27910151e